Vera Therapeutics, Inc.
VERA · Nasdaq · USD · Market cap $1.9B · 339 employees
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price25.45 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.93x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.19)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.19, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Vera Therapeutics, Inc. holds its Markup at $25.45. The statistical read favours the sellers, held for 69 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 69 days |
| Price at the screen | $25.45 |
| Valuation | N/A trailing · -6.69 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.19 |
Five Screens: VERA's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 10.52% | Below 33% | Pass |
| Interest-bearing cash | 48.98% | Below 33% | Fail |
| Receivables | 48.73% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Vera Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 49% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when VERA's ethical verdict changes
Today VERA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.93x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 14 covering, consensus Strong Buy. Average target +195%.
Early stage drug developer lacks financial track record
A clinical stage biotech chasing new treatments for immune diseases can grab attention when analysts line up behind a high price target. Vera sits at 38.50 dollars against a median broker view of 82 dollars and our own fair value of 77 dollars. Yet the opportunity rating sits at none because the ethical screen returns insufficient data and key ratios are missing.
The business shows zero profit margin, negative 71 percent return on equity and a forward multiple of negative 10 times that reflects ongoing losses rather than earnings power. With no moat identified and still pre commercial, the story rests on one candidate drug whose success remains unproven in the market.
Risks centre on the total absence of reliable financial history plus the ethical gap that blocks any further review. Clinical outcomes can shift quickly and funding needs may dilute holders long before any revenue appears. Analysis, not advice.
| Forward P/E | -6.7x |
| EPS, trailing | -5.90 |
| EPS, forward | -3.92 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -113.5%not currently earning a positive return on equity |
| FCF yield | -12.91% |
| Debt to equity | 0.23minimal debt: a conservative balance sheet |
| Current ratio | 7.91comfortably covers its short-term bills |
| Beta | 1.19moves a little more than the market |
| Short interest, float | 0.19% |
| 52-week range | 25.82 - 56.05 |
| Market cap | $1.9B |
| Employees | 339 |
VERA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off to a ... Yahoo Finance · 14d ago
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 15d ago
- Vera Therapeutics Q3 Earnings Call Highlights Yahoo Finance · 15d ago
- Vera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% Run Yahoo Finance · 15d ago
- Vera Therapeutics, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $36.61 | -13.6% | · | $864 | -13.6% |
| 2 months | $45.04 | -29.8% | · | $702 | -29.8% |
| 3 months | $41.17 | -23.2% | · | $768 | -23.2% |
| 6 months | $46.02 | -31.3% | · | $687 | -31.3% |
| 1 year | $22.62 | +39.8% | · | $1,398 | +39.8% |
| 2 years | $38.98 | -18.9% | · | $811 | -18.9% |
| 3 years | $7.77 | +307.0% | · | $4,070 | +307.0% |
| 5 years | $14.61 | +116.4% | · | $2,164 | +116.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever VERA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.